Products for Research Use Only

Moxifloxacin-d4

CAT: 0804-HY-66011ASSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-66011ASSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Moxifloxacin-d4 is the deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
CAS Number
2596386-23-9
Product Name Alternative
BAY 12-8039-d4 (free base)
UNSPSC
12352005
Target
Antibiotic; Bacterial; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Others
Field of Research
Infection
Solubility
10 mM in DMSO
Smiles
O=C(C1=C2C(OC)=C(C(F)=C1)N3C([2H])([2H])[C@@]4([H])NCCC[C@]4(C3([2H])[2H])[H])C(C(O)=O)=CN2C5CC5
Molecular Formula
C21H20D4FN3O4
Molecular Weight
405.46
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52 (5) :1697-702.|[3]Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58 (2) :96-102.|[4]Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58 (5) : p. 379-88.|[5]Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59 (1) :115-39.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
Quinolone